Navigation Links
GeneNews provides Centocor access to its osteoarthritis program
Date:12/11/2008

TORONTO, Dec. 11 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced that it has entered into a agreement allowing Centocor Research & Development, Inc. selected access to research from its osteoarthritis genomic biomarker program. Additional terms of the agreement were not disclosed.

"The Sentinel Principle(TM), our proprietary platform technology for the discovery of blood-based biomarkers, was validated around osteoarthritis, a debilitating joint disease," said Dr. Heiner Dreismann, Lead Director and Interim CEO of GeneNews. "This agreement is a positive reflection of the quality of our research and technology and a source of non-dilutive funding that will contribute to our commercialization efforts."

    About GeneNews
    --------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. For more information on GeneNews, visit www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncert
'/>"/>

SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GeneNews to exhibit ColonSentry(TM) at Family Medicine Forum 2008
2. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
3. GeneNews appoints Canadian Colorectal Cancer Advisory Board
4. GeneNews restructures operations
5. GeneNews appoints Patrick Terry as lead strategic advisor for U.S. commercialization of ColonSentry(TM)
6. GeneNews Announces Second Quarter Results
7. GeneNews launches worlds first blood test for colorectal cancer screening
8. GeneNews announces management changes to support commercialization of ColonSentry(TM)
9. Genenews adds two members to its Board of Directors
10. GeneNews Announces First Quarter Results
11. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... ... Countries, - Competitors Precluded from Immediate Commercialization of Competitive ... Products, ... TSX.V.NTB) announces that the,European Patent Office (EPO) granted on May 31st 2007 Neptune,s composition,of ...
... Expected to Yield Multiple New Drug Products for Aida,s ... ... Calif., March 27 Aida,Pharmaceuticals, Inc (OTC Bulletin Board: AIDA) today ... Jiangsu,Institute of Microbiology Co., Ltd. ("JSIM") Aida,s subsidiary, Hanzhou,Aida Pharmaceuticals Co., ...
... through conversion of agricultural ... products into advanced materials, COLUMBUS, Ohio, ... representing a wide range of expertise in the,fields of chemicals, ... Chemicals, Polymers, and Advanced Materials Task Force. The,creation of the ...
Cached Biology Technology:Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 2Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 3Aida Acquires High-Level Research Institute in China 2Ohio Task Force Begins Mission of Creating a New 21st Century Industry 2Ohio Task Force Begins Mission of Creating a New 21st Century Industry 3
(Date:7/9/2015)... Calif. , July 9, 2015  Unchained ... today announcing its acquisition of Avid Nano. Avid ... light scattering (DLS) systems.    Also ... smallest, fastest and easiest to use protein sizing ... that measures a protein,s hydrodynamic size, size distribution, ...
(Date:7/8/2015)... , July 8, 2015 Summary Pancreatic ... the fourth most fatal, with a mortality rate of ... prognosis of pancreatic cancer patients has highlighted a significant ... is not being met by the current market. ... of products with varying molecule types and mechanisms of ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... 7, 2008 The Global Innovation Imperatives (Gii) ... for their first session at the American Chemical ... Gii, a joint collaboration between the ACS Committee ... Industry, seeks to combat worldwide health, environmental and ...
... is a poorly understood condition that incapacitates and affects the ... In the US, it affects approximately six million women and ... It is a chronic painful disease which occurs when ... the area of the ovaries and fallopian tubes, but can ...
... the fact that millions of Americans are believed to have ... to treat many of these people. That is due in ... are varied and complex, ranging from chronic allergies, viral infection, ... percent of Americans have lost their sense of smell and ...
Cached Biology News:At ACS' national meeting, global initiative set to tackle water issues 2New study finds uncontrollable stress worsens symptoms of endometriosis 2New study finds uncontrollable stress worsens symptoms of endometriosis 3For some who have lost their sense of smell, a once popular asthma drug could help 2For some who have lost their sense of smell, a once popular asthma drug could help 3
Hamster serum...
... Dye Pack, 12 x Cy5. The ... for microarray labeling.Higher reactivity Cy3 and ... per vial, at > 75% reactive ... and packed in foil packs for ...
Collected from sexually mature, mixed sex, mixed breed dogs. Serum from specific breeds available by request....
... Power Supply, 1. 300 V, 400 ... constant current modes.Single-unit increments in settings ... for submarine, mini vertical, and standard ... semidry and mini tank blotting applications. ...
Biology Products: